Vasculitis-like Palpable Purpuric Rush Induced by Decapeptyl in a Pediatric Patient Diagnosed Central Precocious Puberty: A Pediatric Case

Galip N et al. Vasculitis-like Rush Induced by Decapeptyl

Nilufer Galip1, Nermin Ankay2, Ruveyde Bundak3
1Division of Pediatric Allergy and Clinical Immunology, University of Kyrenia, North Cyprus
2Department of Pediatrics, Dr Burhan Nalbantoglu State Hospital, Nicosia, North Cyprus
3Division of Pediatric Endocrinology, University of Kyrenia, North Cyprus

What is already known on this topic?
Drug induced vasculitis is an inflammation of blood vessels caused by pharmaceutical agents and is the most common form of vasculitis. Pathogenesis is not clear yet but many different drugs may cause similar clinical features suggesting a common mechanism. Skin manifestations are most common, following with renal involvement or lung involvement with interstitial pneumonia or acute respiratory distress syndrome. There are several systemic adverse reactions reported due to GRHa treatments including vasculitis-like rushes.

What this study adds?
This case is one of the few pediatric case of CPP experiencing vasculitis-like rushes due to triptorelin (Decapeptyl Depot ®) injection in the literature. It should be kept in mind that in pediatric PCC patients who develop side effects like cutaneous vasculitis, vasculitis-like rushes or other systemic adverse reactions, the treatment may be continued by changing the preparation.

Abstract
Central precocious puberty (CPP) is defined by the appearance of secondary sexual signs in girls younger than 8 years of age or the onset of menarche before the age of 10. Gonadotropin-releasing hormone analogs (GnRHa) are the most effective therapy in CPP. Drug-induced hypersensitivity vasculitis is an inflammation of blood vessels due to the use of several pharmacologic agents. We present the first pediatric case of vasculitis induced by Decapeptyl. 7 years and 3 months old girl admitted to Pediatric Endocrinology outpatient clinic with a complaint of premature breast development. The patient diagnosed CPP with her physical examination and laboratory findings and tripoteline acetate (Decapeptyl ) treatment initiated. She experienced multiple rushes on her body with a mild abdominal pain and high temperature after 8 hours from the second dose of Decapeptyl administration. She hospitalized with the diagnosis of drug-induced vasculitis and single dose of iv methyl-prednisolone 1 mg/kg treatment and oral cetirizine initiated. Her blood and urine analysis revealed no other organ involvement rather than skin. On the third day, all the purpuric lesions started to resolve and completely disappeared on the 6th day. Hereby, we described first pediatric case of CPP experiencing vasculitis due to triptorelin injection. Her treatment for PCC was switched to Depot Leuprolide acetate and she continued her treatment for 2 years uneventfully. It should be kept in mind that in pediatric PCC patients who develop side effects like cutaneous vasculitis, the treatment may be continued by changing the preparation.

Keywords: Drug-induced, central precocious puberty, vasculitis, vasculitis-like rush

Nilufer Galip MD, Department of Pediatrics, Division of Pediatric Allergy and Clinical Immunology, University of Kyrenia, Kyrenia, Cyprus
+90 533 863 27 97
dr_ngalip@yahoo.com
0000-0002-8366-9822
02.08.2021
04.11.2021

Presented in: This case report presented before in 63th Turkish National Pediatric Congress on November 2019 as a poster presentation.

Published: 12 November 2021

Introduction
Central precocious puberty (CPP) is defined by the appearance of secondary sexual signs in girls younger than 8 years of age or the onset of menarche before the age of 10 and may lead to premature epiphysial fusion with compromise in final adult stature (1).

CPP occurs 1 in 5000 to 10,000 children and is more common in girls. The idiopathic form of CPP is usually due to the early maturation of the hypothalamic-pituitary-gonadal (HPG) axis without other pathological causes. Gonadotropin-releasing hormone analogs (GnRHa), which are able to desensitize the pituitary gland by GnRH release are the most effective therapy in CPP. In the early 1980s, several different formulations of GnRHa were developed with
Medication induced clinical syndromes have been seen for many years and several syndromes are described either self-limiting or life threatening. Some may trigger autoimmune events or may confused with autoimmune diseases. Drug induced vasculitis is an inflammation of blood vessels caused by pharmaceutical agents and is the most common form of vasculitis. Inflammation may be short term (acute) or long-term (chronic) with a few or more organ involvement (7). Systemic form of drug induced vasculitis are rarely seen in patients on long term therapy whereas cutaneous vasculitis is more common(8,9).

Drug induced vasculitis usually affect skin and rarely kidneys and lungs(10,11). Pathogenesis is not clear yet but many different drugs may cause similar clinical features suggesting a common mechanism. A type of anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis is described in 2000’s related to long term use of anti-thyroid medications (12). Since then many other drugs such as antibiotics, anti-tumor necrosis factor alpha agents or psychoactive agents are blamed for ANCA-associated vasculitis (7). Detection of ANCA assays and tissue biopsies are recommended for diagnosis and differential diagnosis of drug-induced vasculitis (13,14).

Usually clinical manifestations of drug induced vasculitis are similar with primary vasculitic syndromes. Skin manifestations are most common, following with renal involvement with varying symptoms like hematuria, proteinuria, or elevated serum creatinine (15).

Some patients may suffer only lung involvement with interstitial pneumonia or acute respiratory distress syndrome (16,17). There are no specific laboratory tests for diagnosis of drug-induced vasculitis, however some laboratory markers may help to distinguish drug induced vasculitis from idiopathic autoimmune diseases such as ANCA, Anti-ds DNA antibodies or Antiphospholipid antibodies. Some laboratory findings may indicate organ involvements, anemia is common whereas acute-phase reactants such as erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) which are usually elevated are not sensitive or specific for drug-induced vasculitis (13,18). Our case also presented with anemia and slightly elevated CRP level. Treatment options for drug-induced vasculitis depends on the patients’ individualized maintenance. Depending on clinical course and organ involvement of drug-induced vasculitis there is no standard approach for treatment but first step is the discontinuation of medication as we recommended to our patient. Corticosteroids, cyclophosphamide, azathioprine and mycophenolate mofetil are among the available treatment options (19).
In the literature, there are a few case reports defining vasculitis or vasculitis-like rushes following the treatment with GnRHa. First one was reported in 1993 in a 23-year old woman after the first course of Decapeptyl used for in vitro fertilization procedure (20). The patient experienced purpuric papular rushes similarly to our pediatric case and lesions resolved in a few days with oral antihistamine and topical corticosteroid cream (20). Second one was a 67-year old man experiencing fever, rash and arthritis after the second dose of leuprolide (Lucrin) administration for his prostatic cancer and treated with steroids (6). Another case reported in 2010, was a 26-year old woman with a history of previous autoimmune and neuromuscular disease, experiencing polymyositis and vasculitis 5 days after GnRH analogue (Decapeptyl) administration (21).

Kirkgoz et al. recently reported 9 pediatric cases experienced systemic hypersensitivity reactions to GRHa during the treatment of CPP. One of the cases in this report were quite similar to our case with palpable purpuric rushes on her legs as considered as Henoch-Schönlein Purpura (HSP) by her pediatrician. This case also resolved without treatment in 1 week and the patients treatment switched to Leuprolide acetate successfully (22).

Hereby, we described a pediatric case of CPP experiencing vasculitis-like rushes due to tripotelin (Decapeptyl Depot®) injection. Due to mild clinical course, absence of extracutaneous organ involvement and rapid recovery no further tests or biopsy was required. However there is a limitation for the article that we could not clarify the histopathological diagnosis with biopsy. Her treatment for PCC was switched to Depot Leuprolide acetate (Lucrin Depot® 11,25/ 3 months) and she continued her treatment for 2 years uneventfully. This makes us think that apart from the active ingredient of the drug, solvents may also cause such side effects. It should be kept in mind that in pediatric PCC patients who develop side effects like cutaneous vasculitis, the treatment may be continued by changing the preparation.

References


Table 1. LHRH stimulation test results

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>LH mIU/ml</th>
<th>FSH mIU/ml</th>
<th>Estradiol pg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.34</td>
<td>4.33</td>
<td>16</td>
</tr>
<tr>
<td>30</td>
<td>5.85</td>
<td>11.94</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>5.61</td>
<td>13.29</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>4.56</td>
<td>14.31</td>
<td>17</td>
</tr>
</tbody>
</table>
Figure 3.